Mitochondria-targeted prostate cancer therapy using a near-infrared fluorescence dye-monoamine oxidase A inhibitor conjugate

Area of Science:

• Oncology
• Biomedical Engineering
• Pharmacology

Background:

• Prostate cancer (PCa) is a leading cause of cancer-related death in men, with limited treatment options for advanced and metastatic stages.
• Hormone-refractory PCa (HRPC) and metastatic PCa present significant therapeutic challenges.
• Increased monoamine oxidase A (MAOA) expression in advanced PCa suggests it as a potential therapeutic target.

Purpose of the Study:

• To develop and evaluate a novel near-infrared fluorescence (NIRF) heptamethine dye–MAOA inhibitor conjugate (NIR-INH) for simultaneous PCa imaging, targeting, and therapy.
• To assess the efficacy of NIR-INH in inhibiting tumor growth and metastasis in PCa models.
• To investigate the safety profile of NIR-INH compared to traditional chemotherapy.

Main Methods:

• Synthesis of a NIRF heptamethine dye–MAOA inhibitor conjugate (NIR-INH).
• Evaluation of NIR-INH's targeting specificity in PCa xenografts.
• Assessment of tumor growth inhibition and survival extension in PCa xenograft models.
• Toxicity evaluation of NIR-INH treatment.

Main Results:

• NIR-INH demonstrated specific targeting in PCa xenografts.
• The conjugate markedly inhibited tumor growth in vivo.
• NIR-INH treatment showed no obvious toxicity, offering a potential advantage over conventional chemotherapy.
• The study highlights the potential of MAOA as a therapeutic target for PCa.

Conclusions:

• NIR-INH is an effective agent for prostate cancer targeting, imaging, and therapy.
• The developed conjugate shows significant anti-tumor effectiveness with a favorable safety profile.
• NIR-INH represents a promising image-guided anti-tumor strategy for prostate cancer treatment.